Catalog No. (SRN958K)  •  US $4,850  •  January 2024


 

Greystone Research Associates is pleased to announce the publication of a new market assessment. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

The report provides developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, opportunities for injection devices that are designed for patient self-administration. Provider organization business managers, healthcare administrators and investors will also benefit from this study.


Evolution in Therapeutic Care

Because of the ongoing need for repeat dosing posed by chronic diseases, these indications represent significant drug volume and revenue opportunities, while simultaneously challenging the industry to develop products that meet the unique needs of the non-professional caregiver. For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges are improving ease-of-use and increasing the alternative device share of the growing self-injection market.

 

Numerous graphs, charts, tables and visualizations complement the analysis

 

Forecasts, projections of future market activity are derived using standard modeling and statistical techniques.

 


What You Will Learn

  • Analyzes and evaluates modified release neurology therapeutics products and assesses the market potential for existing and probable future products
  • Analyzes product strategies, technologies and market development issues
  • Provides detailed analysis of neurology market segments, market demographics, and therapeutic strategies
  • Profiles market sector companies, their product development activities, business strategies, and corporate alliances and affiliations
  • Evaluates the impact of economic, technology, and regulatory factors on neurology drug markets

 


Table of Contents – Modified Release Neurology Therapeutics

Executive Summary

The Market Opportunity

Executive Summary

The Neurological Drug Market Dynamics

The Trend Toward Self-Administration

Route of Administration

Innovation in Drug Formulation

Neurological Drugs and As-supplied Packaging

Human Engineering/Ergonomics

Delivering Neurological Drugs via Injection

Primary Packaging

Innovation in Injectable Device Designs

Drug Delivery Device Selection Issues

Therapeutic Demand Drivers

Key Market Factors

MR Neurological Product Analysis

Proprietary Formulation Technology

ChroniJect (Oakwood Laboratories/PharmaSophia)

CriticalMix (Critical Pharmaceuticals)

Depofoam (Pacira)

FluidCrystal (Camarus)

LinkeRx (Alkermes)

Medisorb (Alkermes)

Medusa (Recipharm/Avadel)

Nanocrystals (Alkermes)

Optisomes (Talon/Spectrum)

PolyActive (Octoplus)

Q-Sphera (Midatech Pharma)

SABER/SAIB (DURECT)

SynBiosys (Innocore)

TransCon (Ascendis)

Physical Process Control Methods

Supercritical Fluid

SCF for Nanoparticle Formulations

Formulplex (Supercritical Solutions)

Ferro

SCF extraction of emulsions (SFEE)

Stability

Administration Factors

Therapeutic Market Sectors

Schizophrenia

Bipolar Disorder

Market Sector Analysis and Forecasts

Key Market Factors

Economic Factors

Technology Factors

Regulatory Factors

Risk Factors

Forecasts and Market Data

Company Profiles

 

Self-administered Injectable Drug Therapies

 

Order Online

 

 

 


 

This Report is also available from Global Information, Inc.